Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / Prostate Specimen Ref Set Applicant: Isaacs-JHU-2010

Prostate Specimen Ref Set Applicant: Isaacs-JHU-2010

14 SNPs
Prostate and Urologic Cancers Research Group

Can SNP genotyping assist in the prediction of biopsy results for prostate cancer.

As an initial quality control for the genotyping data, tests for Hardy-Weinberg equilibrium are performed for each SNP among control subjects using Fisher's exact test. The number of risk alleles of the 14 SNPs, is counted for each subject. Men are classified into eight approximately equal sized groups based on number of risk alleles 8;.7, 8, 9,10,11,12,13, and ~14). Number of risk alleles is modeled as a categorical variable with men who had 11 risk alleles (mode) serving as the 398/2590 (Rev. 06/09) Pags_ Continuation Format Page Program Director/Principallnvestigator (Last, First, Middle): baseline group. ORs for positive biopsy of PCa for men with various combinations of number of risk alleles will be estimated from regression coefficients of these variables in the logistic regression model. Absolute risk will be estimated based on the OR, calibrated incidence rate of PCa for men with the most common number of risk alleles, and mortality rate for all causes excluding PCa in the U.S. The calibrated incidence rates will be calculated based on jOint attributable risk of number of risk alleles estimated from the data and population incidence rates in the U.S. (2006 data). The initial set of 100 samples will allow us to assess the feasibility of this analysis in terms of having sufficient DNA, DNA quality and genotyping call rates and reproducibility. Following completion of this analysis for the first 100 samples additional samples will be requested to increase the power of the study to provide stable positive biopsy risk rates.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.